DiaMedica Therapeutics Inc (DMAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $474.29M
Last updated: Nov 17, 2026 at 11:03 AM ET
DiaMedica Therapeutics Inc (DMAC) Earnings: Report Dates and Results
DiaMedica Therapeutics (DMAC) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, DiaMedica Therapeutics reported EPS of -$0.21, below the -$0.20 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DMAC has an expected report date of Mar 29, 2027.
DMAC Earnings Call
The latest DMAC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, DMAC beat 19, missed 14 and matched 5. The widest gap in the table came in the quarter ended Jun 30, 2018, when EPS landed 275.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.21 | -$0.20 | -$0.23 - -$0.19 | -5.00% | Miss | N/A | 4 | 1 up, 0 down | Nov 12, 2026 |
| Jun 30, 2026 | -$0.19 | -$0.19 | -$0.21 - -$0.19 | 0.00% | In line | N/A | 4 | 2 up, 1 down | Aug 10, 2026 |
| Mar 31, 2026 | -$0.19 | -$0.18 | -$0.20 - -$0.17 | -5.56% | Miss | N/A | 4 | 2 up, 1 down | May 6, 2026 |
| Dec 31, 2025 | -$0.17 | -$0.18 | -$0.20 - -$0.17 | +2.86% | Beat | N/A | 4 | 0 up, 3 down | Mar 30, 2026 |
| Sep 30, 2025 | -$0.17 | -$0.16 | -$0.17 - -$0.15 | -6.25% | Miss | N/A | 3 | 3 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.18 | -$0.19 | -$0.22 - -$0.17 | +5.26% | Beat | N/A | 3 | 0 up, 2 down | Aug 12, 2025 |
| Mar 31, 2025 | -$0.18 | -$0.18 | -$0.19 - -$0.17 | 0.00% | In line | N/A | 3 | 0 up, 0 down | May 13, 2025 |
| Dec 31, 2024 | -$0.18 | -$0.17 | -$0.18 - -$0.16 | -4.35% | Miss | N/A | 4 | 1 up, 2 down | Mar 17, 2025 |
| Sep 30, 2024 | -$0.15 | -$0.15 | -$0.19 - -$0.13 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$0.13 | -$0.16 | -$0.16 - -$0.15 | +18.75% | Beat | N/A | 3 | 1 up, 0 down | Aug 7, 2024 |
| Mar 31, 2024 | -$0.14 | -$0.16 | -$0.16 - -$0.15 | +12.50% | Beat | N/A | 3 | 0 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$0.14 | -$0.14 | -$0.14 - -$0.14 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Mar 19, 2024 |
| Sep 30, 2023 | -$0.12 | -$0.13 | -$0.14 - -$0.11 | +7.69% | Beat | N/A | 3 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$0.16 | -$0.18 | -$0.22 - -$0.15 | +11.11% | Beat | N/A | 3 | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.20 | -$0.16 | -$0.18 - -$0.14 | -25.00% | Miss | N/A | 3 | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$0.14 | -$0.14 | -$0.18 - -$0.12 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Mar 28, 2023 |
| Sep 30, 2022 | -$0.12 | -$0.15 | -$0.18 - -$0.12 | +20.00% | Beat | N/A | 4 | 1 up, 0 down | Nov 9, 2022 |
| Jun 30, 2022 | -$0.13 | -$0.18 | -$0.23 - -$0.15 | +27.78% | Beat | N/A | 4 | 1 up, 0 down | Aug 10, 2022 |
| Mar 31, 2022 | -$0.13 | -$0.21 | -$0.32 - -$0.15 | +38.10% | Beat | N/A | 3 | 0 up, 0 down | May 4, 2022 |
| Dec 31, 2021 | -$0.11 | -$0.18 | -$0.22 - -$0.14 | +38.89% | Beat | N/A | 5 | 0 up, 0 down | Mar 14, 2022 |
| Sep 30, 2021 | -$0.18 | -$0.23 | -$0.34 - -$0.19 | +21.74% | Beat | N/A | 6 | 1 up, 0 down | Nov 10, 2021 |
| Jun 30, 2021 | -$0.17 | -$0.22 | -$0.33 - -$0.17 | +22.73% | Beat | N/A | 6 | N/A | Aug 11, 2021 |
| Mar 31, 2021 | -$0.19 | -$0.22 | -$0.28 - -$0.15 | +13.64% | Beat | N/A | 6 | N/A | May 5, 2021 |
| Dec 31, 2020 | -$0.23 | -$0.17 | -$0.21 - -$0.13 | -35.29% | Miss | N/A | 5 | N/A | Mar 10, 2021 |
| Sep 30, 2020 | -$0.19 | -$0.15 | N/A | -26.67% | Miss | N/A | N/A | N/A | Nov 4, 2020 |
| Jun 30, 2020 | -$0.17 | -$0.13 | N/A | -30.77% | Miss | N/A | N/A | N/A | Aug 11, 2020 |
| Mar 31, 2020 | -$0.19 | -$0.28 | N/A | +32.14% | Beat | N/A | N/A | N/A | May 13, 2020 |
| Dec 31, 2019 | -$0.21 | -$0.25 | N/A | +16.00% | Beat | N/A | N/A | N/A | Mar 23, 2020 |
| Sep 30, 2019 | -$0.20 | -$0.21 | N/A | +4.76% | Beat | N/A | N/A | N/A | Nov 13, 2019 |
| Jun 30, 2019 | -$0.21 | -$0.26 | N/A | +19.23% | Beat | N/A | N/A | N/A | Aug 13, 2019 |
| Mar 31, 2019 | -$0.27 | -$0.20 | N/A | -35.00% | Miss | N/A | N/A | N/A | May 13, 2019 |
| Dec 31, 2018 | -$0.23 | -$0.20 | N/A | -15.00% | Miss | N/A | N/A | N/A | Mar 19, 2019 |
| Sep 30, 2018 | -$0.07 | -$0.16 | N/A | +56.25% | Beat | N/A | N/A | N/A | Nov 19, 2018 |
| Jun 30, 2018 | -$0.60 | -$0.16 | N/A | -275.00% | Miss | N/A | N/A | N/A | Aug 29, 2018 |
| Mar 31, 2018 | -$0.20 | -$0.16 | N/A | -25.00% | Miss | -200.0% | N/A | N/A | Apr 30, 2018 |
| Sep 30, 2017 | -$0.17 | -$0.16 | N/A | -6.25% | Miss | N/A | N/A | N/A | Nov 27, 2017 |
| Jun 30, 2017 | -$0.20 | -$0.14 | N/A | -42.86% | Miss | N/A | N/A | N/A | Aug 29, 2017 |
| Mar 31, 2017 | $0.20 | -$0.16 | N/A | +225.00% | Beat | N/A | N/A | N/A | Apr 27, 2017 |
| Sep 30, 2016 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 29, 2016 |
| Jun 30, 2016 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 29, 2016 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.70, after -$0.60 the year before. It was -$2.28 for the year ended Dec 31, 2012, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.70 | N/A |
| Dec 31, 2024 | -$0.60 | N/A |
| Dec 31, 2023 | -$0.62 | N/A |
| Dec 31, 2022 | -$0.52 | N/A |
| Dec 31, 2021 | -$0.65 | N/A |
| Dec 31, 2020 | -$0.78 | N/A |
| Dec 31, 2019 | -$0.89 | N/A |
| Dec 31, 2018 | -$5.83 | N/A |
| Dec 31, 2012 | -$2.28 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,211 | 8 | |
| 2026Q2 | Jun 30, 2026 | 3,945 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,212 | 8 | |
| 2025Q4 | Dec 31, 2025 | 4,191 | 9 | |
| 2025Q3 | Sep 30, 2025 | 2,943 | 8 | |
| 2025Q2 | Jun 30, 2025 | 2,766 | 6 | |
| 2025Q1 | Mar 31, 2025 | 2,453 | 6 | |
| 2024Q4 | Dec 31, 2024 | 3,983 | 8 |
2026Q3 Earnings Call
Opening remarks
Rick Pauls President and CEO Thank you, operator, and good morning, everyone. Thank you for joining our third quarter earnings call. With me today are Dr. Julie Krop, our chief medical officer, and Scott Kellen, our chief financial officer. Since our last earnings call, we achieved two major clinical milestones. First, enrollment was completed in the first two cohorts of the investigator-sponsored phase 2 early-onset fetal growth restriction study. Second, in October, we enrolled the 200th participant in ReMEDy2, our pivotal phase 2/3 trial in acute ischemic stroke. With this, we attained the prespecified enrollment threshold required for the ReMEDy2 interim analysis. Together, these milestones bring us closer to important clinical readouts that could help define the next stage of development for DM199 in fetal growth restriction, preeclampsia, and acute ischemic stroke. We are also continuing to prepare for additional studies in preeclampsia, including our company-sponsored phase 2 trial, and made progress addressing FDA feedback on the nonclinical package needed for a U.S. investigational new drug application for preeclampsia. I will walk through the major updates. Julie will discuss the clinical objectives in more detail, and Scott will review our financial results. As a reminder, DM199, generic name rinbifetapenem alfa, is a recombinant form of human tissue kallikrein-1, or KLK1. Through activation of the bradykinin-2 receptor pathway, we believe DM199 has the potential to improve vascular health and function, ultimately improving blood flow. This is a completely novel mechanism of action and provides a common therapeutic rationale across preeclampsia, fetal growth restriction, acute ischemic stroke, and other diseases, even though the clinical objectives and endpoints differ across these indications. Let me begin with the early-onset fetal growth restriction program, or FGR. Professor Cluver has now completed enrollment in the first two cohorts of the phase 2 study being conducted at Tygerberg Hospital in Cape Town, South Africa. Together, these cohorts include 12 participants, with six treated at 5 micrograms per kg and six treated at 10 micrograms per kg. This is the first clinical evaluation of DM199 in women with early-onset fetal growth restriction. Early-onset FGR is a pregnancy disorder associated with significant risks to the fetus, frequently resulting from placental insufficiency, creating impaired blood flow that restricts the supply of oxygen and nutrients to the baby. Currently, no therapy is approved to treat FGR. The only option today for physicians is to closely monitor both mother and baby, balancing the risk of stillbirth and fetal complications from worsening placental function against the serious neonatal risk of delivering very prematurely. In pregnancies complicated by preeclampsia, maternal risk also includes severe hypertension and organ injury.
Frequently Asked Questions About DMAC
When is DiaMedica Therapeutics's next earnings date?
DiaMedica Therapeutics's next earnings report is expected for Mar 29, 2027.
Did DMAC beat earnings estimates last quarter?
No. DiaMedica Therapeutics reported EPS of -$0.21 for the quarter ended Sep 30, 2026, below the -$0.20 estimate by 5.00%.
What EPS do analysts expect from DMAC next quarter?
The consensus EPS estimate for DiaMedica Therapeutics for the quarter ending Dec 31, 2026 is -$0.23 from 6 analysts, with estimates from -$0.25 to -$0.20.
How often does DMAC beat earnings estimates?
DiaMedica Therapeutics beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -1.63%.
DMAC pages: Overview, Earnings, Forecast, Financials, Competitors